Skip to main content
. 2023 Mar 28;15(4):1085. doi: 10.3390/pharmaceutics15041085

Figure 2.

Figure 2

Effects of S63845 treatment on the hematopoietic stem/progenitor cells of CB6F1 mice. (A) Representative FACS profiles of LT-HSC, ST-HSC, and MPP subpopulations in BM and SP LKS+ cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (B) Percentage of LT-HSC, ST-HSC, and MPP populations in BM (upper panel) and SP (lower panel) LKS+ cells, as described in (A). Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (C) Representative FACS profiles of LT-HSC, ST-HSC, and MPP subpopulations in BM and SP LKS+ cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (D) Percentage of LT-HSC, ST-HSC, and MPP populations in BM (upper panel) and SP (lower panel) LKS+ cells, as described in (C). Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. All data represent the means ± SEM compared with control unless otherwise specified. * p < 0.05, ** p < 0.01, *** p < 0.001, and ns = not significant according to two-tailed unpaired Students’ t-test. LT-HSC: long-term hematopoietic stem cell; ST-HSC: short-term hematopoietic stem cell; MPP: multipotent progenitor; LKS+: Lin−c-Kit+Sca-1+.